Abbott Laboratories $ABT Shares Sold by Prospector Partners LLC

Prospector Partners LLC trimmed its position in Abbott Laboratories (NYSE:ABT) by 5.1% during the 3rd quarter, HoldingsChannel reports. The institutional investor owned 133,334 shares of the healthcare product maker’s stock after selling 7,096 shares during the quarter. Abbott Laboratories comprises about 2.1% of Prospector Partners LLC’s portfolio, making the stock its 12th biggest holding. Prospector Partners LLC’s holdings in Abbott Laboratories were worth $17,859,000 at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in the company. Brighton Jones LLC raised its stake in Abbott Laboratories by 10.1% in the 4th quarter. Brighton Jones LLC now owns 51,719 shares of the healthcare product maker’s stock valued at $5,850,000 after purchasing an additional 4,755 shares during the last quarter. Sivia Capital Partners LLC boosted its stake in Abbott Laboratories by 3.5% during the 2nd quarter. Sivia Capital Partners LLC now owns 4,768 shares of the healthcare product maker’s stock worth $648,000 after purchasing an additional 162 shares during the last quarter. United Bank grew its holdings in shares of Abbott Laboratories by 7.4% during the second quarter. United Bank now owns 29,004 shares of the healthcare product maker’s stock worth $3,945,000 after buying an additional 2,001 shares in the last quarter. Cullen Frost Bankers Inc. raised its position in shares of Abbott Laboratories by 1.1% in the second quarter. Cullen Frost Bankers Inc. now owns 171,265 shares of the healthcare product maker’s stock valued at $23,294,000 after buying an additional 1,818 shares during the last quarter. Finally, Retirement Planning Group LLC lifted its stake in shares of Abbott Laboratories by 3.3% in the second quarter. Retirement Planning Group LLC now owns 3,441 shares of the healthcare product maker’s stock worth $468,000 after buying an additional 109 shares in the last quarter. Institutional investors and hedge funds own 75.18% of the company’s stock.

Insider Transactions at Abbott Laboratories

In other news, Director Daniel J. Starks bought 10,000 shares of the stock in a transaction that occurred on Wednesday, February 4th. The stock was bought at an average cost of $108.73 per share, for a total transaction of $1,087,300.00. Following the acquisition, the director directly owned 6,738,817 shares of the company’s stock, valued at $732,711,572.41. The trade was a 0.15% increase in their position. The purchase was disclosed in a filing with the SEC, which is available at the SEC website. Insiders own 0.46% of the company’s stock.

Analyst Ratings Changes

Several analysts recently issued reports on the stock. Piper Sandler dropped their price objective on shares of Abbott Laboratories from $150.00 to $135.00 and set an “overweight” rating for the company in a research note on Friday, January 23rd. Citigroup cut their price target on Abbott Laboratories from $155.00 to $140.00 and set a “buy” rating for the company in a report on Friday, January 23rd. Oppenheimer lowered their price objective on Abbott Laboratories from $140.00 to $132.00 and set an “outperform” rating on the stock in a research note on Friday, January 23rd. Evercore dropped their target price on Abbott Laboratories from $144.00 to $138.00 and set an “outperform” rating for the company in a report on Friday, January 23rd. Finally, Weiss Ratings lowered Abbott Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a report on Monday, January 26th. Two analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and four have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $137.05.

Abbott Laboratories Price Performance

ABT stock opened at $113.32 on Thursday. Abbott Laboratories has a 52-week low of $105.27 and a 52-week high of $141.23. The business has a fifty day moving average of $118.94 and a two-hundred day moving average of $126.10. The stock has a market cap of $197.05 billion, a price-to-earnings ratio of 30.46, a price-to-earnings-growth ratio of 1.79 and a beta of 0.75. The company has a quick ratio of 1.24, a current ratio of 1.70 and a debt-to-equity ratio of 0.23.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings results on Thursday, January 22nd. The healthcare product maker reported $1.50 earnings per share for the quarter, hitting analysts’ consensus estimates of $1.50. Abbott Laboratories had a return on equity of 17.94% and a net margin of 14.72%.The business had revenue of $11.46 billion during the quarter, compared to analysts’ expectations of $11.80 billion. During the same period in the prior year, the business posted $1.34 EPS. The company’s revenue was up 4.4% compared to the same quarter last year. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. As a group, research analysts anticipate that Abbott Laboratories will post 5.14 earnings per share for the current year.

Abbott Laboratories Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, February 13th. Investors of record on Thursday, January 15th were issued a $0.63 dividend. The ex-dividend date was Thursday, January 15th. This represents a $2.52 annualized dividend and a dividend yield of 2.2%. This is a boost from Abbott Laboratories’s previous quarterly dividend of $0.59. Abbott Laboratories’s dividend payout ratio (DPR) is presently 67.74%.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.